Abstract:BACKGROUND: Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to their limited effectiveness in accordance with the heterogeneity of cancer cells, there is a constant search for therapeutic approaches with improved outcome, such as immunotherapy that utilizes and enhances the normal capacity of the patient's immune system.METHODS: Chimeric Antigen Receptor (CAR) T-cell therapy involves genetic modification of patient's autologous T-cells to express a CAR specific for a tumor antigen, following by ex vivo cell expansion and re-infusion back to the patient. CARs are fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. This T-cell genetic modification may occur either via viral-based gene transfer methods or nonviral methods, such as DNA-based transposons, CRISPR/Cas9 technology or direct transfer of in vitro transcribed-mRNA by electroporation.RESULTS: Clinical trials have shown very promising results in end-stage patients with a full recovery of up to 92% in Acute Lymphocytic Leukemia. Despite such results in hematological cancers, the effective translation of CAR T-cell therapy to solid tumors and the corresponding clinical experience is limited due to therapeutic barriers, like CAR T-cell expansion, persistence, trafficking, and fate within tumors.CONCLUSION: In this review, the basic design of CARs, the main genetic modification strategies, the safety matters as well as the initial clinical experience with CAR T-cells are described.

CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases

CAR T therapy beyond cancer: the evolution of a living drug

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Chimeric Antigen Receptor T-cell Therapy Beyond Cancer: Current Practice and Future Prospects.

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

The progress of CAR-T therapy in cancer and beyond

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

Current progress in CAR-T cell therapy for tumor treatment

CAR T cell immunotherapy in hematology and beyond

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR T cells: Building on the CD19 paradigm

CAR-T Cell Therapy for Hematological Malignancies: History, Status and Promise

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

CAR-T Cells for Cancer Immunotherapy—the Barriers Ahead and the Paths Through

Driving CAR T-cells forward